Impact of Linagliptin on Cardiovascular (CV) Risk in Type 2 Diabetes (T2D): Insights From a Pre-defined CV Meta-Analysis

被引：0

作者：

Rosenstock, Julio ^{[1
]}

Marx, Nikolaus ^{[2
]}

Neubacher, Dietmar ^{[3
]}

Seck, Thomas ^{[4
]}

Patel, Sanjay ^{[5
]}

Woerle, Hans-Juergen ^{[4
]}

Johansen, Odd Erik ^{[4
]}

机构：

[1] Dallas Diabet & Endocrine Cntr, Dallas, TX USA

[2] Univ Hosp Aachen, Dept Internal Med 1, Aachen, Germany

[3] Boehringer Ingelheim GmbH & Co KG, Global Biometr & Datamanagement, Biberach, Germany

[4] Boehringer Ingelheim KG, Therapeut Area Metab, Ingelheim, Germany

[5] Boehringer Ingelheim GmbH & Co KG, Therapeut Area Metab, Bracknell, Berks, England

来源：

关键词：

Glucose; Type; 2; Diabetes; Vascular disease; Drugs;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

14434

引用

页数：2